text: Administration of the same dose of a drug to all patients has the advantages of simplicity and ease of use.  However, data regarding the variability in platelet inhibition across patients highlights the potential importance of tailoring the antiplatelet or dose of an antiplatelet to the pharmacodynamic response of the patient.  Patients who do not achieve adequate inhibition in response to a dose of<unk>  are variably termed<unk>  non-responders” or<unk>  hyporesponders”.  A recent European Society of Cardiology working group has suggested the term "elevated platelet reactivity despite treatment".
  This chapter reviews the underlying etiology and clinical relevance of<unk>  non-responsiveness.
option_0: Clopidogrel resistance
option_1: Aspirin desensitization
option_2: Activated protein C resistance
option_3: Clubbing pathophysiology
option_4: Warfarin over anticoagulation
option_5: Intraprocedural stent thrombosis
option_6: No-reflow phenomenon
option_7: High density lipoprotein pathophysiology